Catalyst Biosciences

Powered by    favicon Technavio

Catalyst Biosciences | Data-Driven Analysis and Industry Review

Published: August 23, 2024

Catalyst Biosciences - Overview

Catalyst Biosciences is a biopharmaceutical company specializing in the development and commercialization of innovative therapeutics based on its proprietary protein engineering technology. The company's lead product candidates are designed to address unmet medical needs in hematology and neuroscience. Catalyst's Marzeptacog Alfa (activated) or MarzAA is a next-generation engineered Factor VIIa therapeutic with potential for use in hemophilia A and other bleeding disorders. The company's mission is to develop transformative medicines for patients with significant unmet medical needs, leveraging its advanced protein engineering capabilities to create novel therapeutics with improved efficacy, safety, and convenience. Catalyst Biosciences is headquartered in South San Francisco, California.'

Competitive Insights

1. Focus on developing and commercializing protease therapeutics for various indications: Catalyst Biosciences specializes in creating novel protease therapeutics for different diseases, including hemophilia, thrombosis, and other conditions.

2. Proprietary technology platform: The company utilizes its proprietary TransCon technology to develop fusion proteins with extended circulation times and improved therapeutic effects.

3. Collaborations and partnerships: Catalyst Biosciences has collaborations with leading pharmaceutical companies like Pfizer and AstraZeneca, as well as academic institutions, to expand its research and development capabilities.

4. Clinical development pipeline: The company has a robust clinical development pipeline, with several programs in late-stage clinical trials, including Marzeptacog alfa (MZPC) for the treatment of hemophilia A and TransCon PCSF for the treatment of idiopathic pulmonary fibrosis.

5. Strong intellectual property position: Catalyst Biosciences holds a significant number of patents related to its protease therapeutics and TransCon technology, providing a competitive edge in the market.

Business insights

1. Catalyst Biosciences specializes in developing and commercializing innovative protein therapeutics for various diseases, focusing on hemostasis and oncology indications.

2. They employ a proprietary technology platform, Catalytic Antibody Technology (CAT), to design, develop, and manufacture high-purity recombinant proteins and antibodies.

3. The company's lead product, Marzeptacog alfa (activated), is a recombinant Factor VIIa therapeutic for the treatment of bleeding disorders, and is approved in the US and Europe.

4. Catalyst Biosciences also has a pipeline of investigational candidates, including CB 2679, a potential treatment for hemorrhage in cancer patients, and CB 280, a potential treatment for idiopathic thrombocytopenia purpura (ITP).

5. The company's business intelligence is data-driven and focused on market analysis, competitive intelligence, and strategic planning to support the development and commercialization of their innovative therapeutics.

 

infographic

Catalyst Biosciences Market Portfolio | Comprehensive Overview

Browse Our Research Portfolio In Catalyst Biosciences Markets

infographic

Catalyst Biosciences features in

Industries

Health Care

Segments

Pharmaceuticals

Markets

Pharmaceuticals

About Technavio

With unparalleled market insights, our research is designed to elevate your business to new heights. Technavio stands at the forefront of market research with a global perspective. Our approach is grounded in four key principles: accessible reports, comprehensive industry analysis, a focus on innovative and emerging technologies, and competitive pricing. We are dedicated to empowering companies and executives to make informed, timely, and strategic decisions.